NASDAQ:OMCL Omnicell (OMCL) Stock Price, News & Analysis $31.09 +0.59 (+1.93%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$31.38 +0.30 (+0.95%) As of 08/6/2025 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Omnicell Stock (NASDAQ:OMCL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Omnicell alerts:Sign Up Key Stats Today's Range$30.32▼$31.2850-Day Range$26.88▼$31.6852-Week Range$22.66▼$55.74Volume523,445 shsAverage Volume550,122 shsMarket Capitalization$1.46 billionP/E Ratio62.18Dividend YieldN/APrice Target$45.33Consensus RatingModerate Buy Company Overview Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas. Read More Omnicell Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreOMCL MarketRank™: Omnicell scored higher than 72% of companies evaluated by MarketBeat, and ranked 536th out of 1,841 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingOmnicell has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageOmnicell has only been the subject of 3 research reports in the past 90 days.Read more about Omnicell's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth13.76% Earnings GrowthEarnings for Omnicell are expected to grow by 13.76% in the coming year, from $1.09 to $1.24 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Omnicell is 62.18, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.61.Price to Earnings Ratio vs. SectorThe P/E ratio of Omnicell is 62.18, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.32.Price to Earnings Growth RatioOmnicell has a PEG Ratio of 8.90. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioOmnicell has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.08% of the outstanding shares of Omnicell have been sold short.Short Interest Ratio / Days to CoverOmnicell has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Omnicell has recently decreased by 11.57%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOmnicell does not currently pay a dividend.Dividend GrowthOmnicell does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.08% of the outstanding shares of Omnicell have been sold short.Short Interest Ratio / Days to CoverOmnicell has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Omnicell has recently decreased by 11.57%, indicating that investor sentiment is improving significantly. News and Social Media3.7 / 5News Sentiment0.60 News SentimentOmnicell has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Omnicell this week, compared to 6 articles on an average week.Search Interest1 people have searched for OMCL on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Omnicell to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Omnicell insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.52% of the stock of Omnicell is held by insiders.Percentage Held by Institutions97.70% of the stock of Omnicell is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Omnicell's insider trading history. Receive OMCL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter. Email Address OMCL Stock News HeadlinesOmnicell management to meet with KeyBanc4 hours ago | msn.comOmnicell, Inc. (OMCL) Q2 2025 Earnings Conference Call TranscriptAugust 1, 2025 | seekingalpha.comOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce competitors, dethroning the AI Chip King. But there's a critical component that AI data centers need just as badly as chips. The demand is so massive that a single data center uses enough of it to stretch around the earth eight times. While the media hypes up AI chips, the smart money has found the next big thing. Discover Futurist Eric Fry's "Nvidia-killer" stock ideas. | InvestorPlace (Ad)Omnicell, Inc. 2025 Q2 - Results - Earnings Call PresentationAugust 1, 2025 | seekingalpha.comOmnicell Shares Climb Over 2% After Second Quarter Results Surpass ExpectationsAugust 1, 2025 | msn.comQ2 2025 Omnicell Inc Earnings Call TranscriptAugust 1, 2025 | gurufocus.comOmnicell (NASDAQ:OMCL) Reports Upbeat Q2, Full-Year Outlook Slightly Exceeds ExpectationsAugust 1, 2025 | msn.comOmnicell Q2 Earnings: Market Ignoring The SegmentsJuly 31, 2025 | seekingalpha.comSee More Headlines OMCL Stock Analysis - Frequently Asked Questions How have OMCL shares performed this year? Omnicell's stock was trading at $44.52 on January 1st, 2025. Since then, OMCL stock has decreased by 30.2% and is now trading at $31.09. How were Omnicell's earnings last quarter? Omnicell, Inc. (NASDAQ:OMCL) released its quarterly earnings results on Thursday, July, 31st. The company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.30 by $0.15. The business's revenue for the quarter was up 5.0% compared to the same quarter last year. Read the conference call transcript. Does Omnicell have any subsidiaries? Omnicell subsidiaries include these companies: MarkeTouch Media LLC, ReCept Pharmacy, FDS Amplicare, 340B Link Business, InPharmics, Ateb Inc., Aesynt, and others. Who are Omnicell's major shareholders? Top institutional shareholders of Omnicell include Sumitomo Mitsui Trust Group Inc. (3.04%), Bank of New York Mellon Corp (0.65%), Bank of Montreal Can (0.39%) and Pier Capital LLC (0.38%). Insiders that own company stock include Randall A Lipps, Peter J Kuipers, Mark W Parrish, Scott Peter Seidelmann, Joanne B Bauer and Christine Marie Mellon. View institutional ownership trends. How do I buy shares of Omnicell? Shares of OMCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Omnicell own? Based on aggregate information from My MarketBeat watchlists, some other companies that Omnicell investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Palo Alto Networks (PANW). Company Calendar Last Earnings7/31/2025Today8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MEDICAL INFO SYS Sub-IndustryHealth Care Technology Current SymbolNASDAQ:OMCL CIK926326 Webwww.omnicell.com Phone(877) 415-9990Fax847-596-3402Employees3,670Year Founded1992Price Target and Rating Average Price Target for Omnicell$45.33 High Price Target$64.00 Low Price Target$34.00 Potential Upside/Downside+45.8%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$0.50 Trailing P/E Ratio62.18 Forward P/E Ratio28.52 P/E Growth8.88Net Income$12.53 million Net Margins2.01% Pretax Margin3.14% Return on Equity4.27% Return on Assets2.44% Debt Debt-to-Equity Ratio0.13 Current Ratio1.42 Quick Ratio1.24 Sales & Book Value Annual Sales$1.11 billion Price / Sales1.31 Cash Flow$3.13 per share Price / Cash Flow9.94 Book Value$26.98 per share Price / Book1.15Miscellaneous Outstanding Shares46,840,000Free Float45,664,000Market Cap$1.46 billion OptionableOptionable Beta0.78 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:OMCL) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omnicell, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Omnicell With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.